# 該藥丸獲准用於成人雌激素受體陽性、HER2陰性乳癌患者。

*biotech · news · 2026-05-01 · Reuters*

## Key points

- FDA核准Veppanu用於第四期雌激素受體陽性、HER2陰性且帶有ESR1突變的乳癌患者。
- Veppanu在624人晚期試驗中，較fulvestrant展現更長的無病進展存活期。
- FDA同時核准Guardant360 CDx，作為識別符合條件患者ESR1突變的伴隨血液檢測。
- 使用Veppanu的患者腫瘤縮小率高於接受注射型荷爾蒙藥物者。

Branded as Veppanu, the pill is authorized for adults with estrogen receptor-positive, HER2-negative breast cancer, which has already spread or ​cannot be removed by surgery. Sign up here. Patients must carry an ESR1 mutation and ​show disease progression after at least one prior hormone therapy, the ⁠agency said. Arvinas CEO Randy Teel told Reuters the approval would give stage-4 ​breast cancer patients a much-needed treatment option. "Patients really are in need of a ​new modality, a new technology and a new way of hitting disease," he said. The FDA's decision was based on a late-stage trial of 624 participants that showed Veppanu helped patients ​survive for longer periods without their breast cancer worsening, compared with the ​older hormone therapy, fulvestrant. Wedbush analyst Robert Driscoll said Veppanu's efficacy appears competitive with other approved ‌breast ⁠cancer treatments, though differences across trials make clear differentiation difficult. He said the drug's tolerability profile looked "compelling." The FDA said patients taking the pill had tumors shrink more often than those given injectable drugs. The pill's label cautions that it can ​affect heart rhythm and ​may harm ⁠an unborn baby. Teel said the company expects to announce a commercialization deal for Veppanu in the coming weeks, after which ​there would be more clarity on pricing. The FDA also ​approved a ⁠companion blood test, Guardant360 CDx, to identify which patients carry the ESR1 mutation and are eligible for the drug. The recommended dose is a 200 mg pill taken ⁠once ​a day with food, until the disease worsens ​or side effects become too severe, the health regulator said. Reporting by Sriparna Roy, Kamal Choudhury and ​Padmanabhan Ananthan in Bengaluru; Editing by Shreya Biswas, Shilpi Majumdar and Sahal Muhammed

**Companies:** Arvinas
**Countries:** United States, India

[Read the full story on Reuters](https://www.reuters.com/business/healthcare-pharmaceuticals/us-fda-approves-pfizer-arvinas-breast-cancer-drug-2026-05-01/)

---

Canonical: https://newsio.io/zh-TW/n/1cdeac19-88d7-4409-a80b-9e17b73c00a9/her2esr1fda624
Summarized by Newsio from Reuters. https://newsio.io/how-it-works